About this episode

This episode discusses recent developments in dermatology related to psoriasis and psoriatic arthritis, including new drug approvals and clinical trial results.

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes:- Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs - TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr - BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB, p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001). - RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous…

More episodes of Rheumnow Podcast

• Seronegative RA Disease Activity (7.17.2026) · July 17, 2026 · 21 min
• What Lies Beneath - Uric Acid Deposition & Imaging · July 15, 2026 · 60 min
• Gout QD clinics - lessons from the Clinic QD307-QD311 · July 13, 2026 · 38 min
• Gout Cavalcade (7.10.2026) · July 10, 2026 · 27 min
• Gout Journal Club · July 8, 2026 · 57 min
• Podcast Replay: Is it Time to Transition MOAs in RA? · July 7, 2026 · 17 min

Explore listener stats, chart rankings, contacts and more on the Rheumnow Podcast podcast page.